This is a £650K award that will allow the team to build on previous work which identified a potential biomarker for decision making in treating oropharyngeal tumors (tonsil and tongue base) and will fund additional work to develop that predictive model.
The DPFS is a key part of MRC’s Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including 'repurposing' of existing therapies.